DBV Technologies S.A. revenue for the last year amounted to 15.73 M USD, the most of which — 15.73 M USD — came from its highest performing source at the moment, Epicutaneous Immunotherapy Products, the year earlier bringing 4.84 M USD. The greatest contribution to the revenue figure was made by France — last year it brought DBV Technologies S.A. 15.73 M USD, and the year before that — 4.84 M USD.